drugset / Trial / NCT05325866
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Timeline
- Start
- 2022-09-23
- Primary completion
- 2026-01-28
- Completion
- 2026-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemarituzumab | Monoclonal antibody | — | Intravenous |